Ultragenyx Pharmaceutical Investor Relations Material
Latest events
Q2 2024
Ultragenyx Pharmaceutical
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies
Latest reports from Ultragenyx Pharmaceutical Inc
Access all reports
Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focuses on the identification, acquisition, development and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe and internationally. It biologic products include Crysvita (burosumab) as an antibody targeting fibroblast growth factor 23 for treatment of X-linked hypophosphatemia; Mepsevii as an enzyme replacement therapy for the treatment of children and adults with mucopolysaccharidosis VII; Dojolvi like evinacumab for treating long-chain fatty acid oxidation disorders; Evkeeza (evinacumab) like ezetimibe for treating homozygous familial hypercholesterolemia.
Key slides for Ultragenyx Pharmaceutical Inc
Q2 2024
Ultragenyx Pharmaceutical Inc
Q2 2024
Ultragenyx Pharmaceutical Inc
Latest articles
Deere & Company: Shaping the Future of Agriculture Since 1837
Detailing the history of agriculture and Deere & Company, all the way from 1837 to the present day.
25 Oct 2024
Intel: Semiconductors & Strategic Inflection Points
Founded in 1968, Intel has been a key player in the American semiconductor industry, with its processors powering computers worldwide.
15 Oct 2024
Our Favorite Spin-off Stories Since 2000
Spin-off motives vary widely across different companies, but the underlying objective remains the same: enhancing long-term shareholder value.
17 Oct 2024
Ticker symbol
RARE
Country
🇺🇸 United States